Inici › Melanoma › Texas › Houston
Assaigs clínics de Melanoma a Houston, TX
59 estudis de Melanoma busquen participants en centres de Houston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
ReclutantFase 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
ReclutantFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of BI 3810944 in Patients With Advanced Cancer
ReclutantFase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
ReclutantFase 3
- The University of Texas MD Anderson Cancer Center, Houston
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
ReclutantFase 2
- MD Anderson Cancer Center, Houston
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
ReclutantFase 2
- UT MD Anderson Cancer Center, Houston
Pan-tumor MRD Study
ReclutantEstudi observacional
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
Intratumoral N17350 in Advanced Solid Tumors
ReclutantFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
ReclutantFase 1
- M D Anderson Cancer Center, Houston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
ReclutantFase 2
- Local Institution - 0085, Houston
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
ReclutantFase 1/2
- University of Texas-MD Anderson, Houston
- Lumi Research, Houston
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
ReclutantFase 1
- MD Anderson, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
ReclutantFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
ReclutantFase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
ReclutantFase 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
ReclutantEstudi observacional
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
ReclutantEstudi observacional
- M D Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
ReclutantFase 1/2
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
ReclutantFase 1/2
- Houston Methodist Hospital, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
ReclutantFase 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutantFase 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
ReclutantFase 2
- M D Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
ReclutantFase 1/2
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
ReclutantFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
ReclutantFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
ReclutantFase 1
- M D Anderson Cancer Center, Houston
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
Reclutant
- M D Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
ReclutantFase 2
- USA12-0, Houston
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Reclutant
- M D Anderson Cancer Center, Houston
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
ReclutantEstudi observacional
- M D Anderson Cancer Center, Houston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
ReclutantFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
ReclutantFase 3
- Retina Consultants of Texas - (Houston), Houston
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
ReclutantEstudi observacional
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
ReclutantEstudi observacional
- M D Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Reclutant
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
ReclutantFase 1
- University of Texas MD Anderson Cancer Center, Houston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
ReclutantFase 2/3
- The University Of Texas Md Anderson Cancer Center, Houston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
ReclutantFase 3
- Houston Methodist Hospital/Houston Methodist Cancer Center, Houston
ACTengine® IMA203 Combined With mRNA-4203
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
ReclutantFase 3
- The University of Texas M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
ReclutantFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Houston
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
BostonGene and Exigent Genomic INsight Study
ReclutantEstudi observacional
- Oncology Consultants, Houston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
ReclutantFase 1/2
- Oncology Consultants, P.A., Houston
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
ReclutantFase 2
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Reclutant
- The University of Texas MD Anderson Cancer Center, Houston
Assaigs de Melanoma en altres ciutats
- New York City, NY38 estudis
- Los Angeles, CA34 estudis
- Nashville, TN33 estudis
- Pittsburgh, PA31 estudis
- Boston, MA26 estudis
- Philadelphia, PA23 estudis
- San Francisco, CA22 estudis
- Durham, NC21 estudis
- Atlanta, GA21 estudis
- St. Louis, MO21 estudis
- Salt Lake City, UT21 estudis
- Columbus, OH21 estudis
Altres estudis a Houston
- Càncer de pulmó de cèl·lules no petites145 estudis
- Càncer de mama126 estudis
- Càncer (tots els tipus)121 estudis
- Càncer metastàtic104 estudis
- Càncer colorrectal102 estudis
- Càncer d'ovari89 estudis
- Leucèmia mieloide aguda85 estudis
- Càncer de pulmó78 estudis
- Càncer de pròstata76 estudis
- Càncer d'endometri68 estudis
- Càncer de pàncrees61 estudis
- Carcinoma de cèl·lules escamoses de cap i coll47 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.